Innoventric catheter valve
Innoventric catheter valve
Innoventric catheter valve
News summary

Innoventric, an Israeli startup specializing in transcatheter tricuspid regurgitation (TR) treatment, has secured $28.5 million in Series B funding led by RA Capital Management, bringing its total funding to $41 million since its inception in 2017. The newly raised capital will be used to advance clinical trials and expand regulatory approvals in the U.S. and Europe, following successful completion of a first-in-human clinical trial in Europe. Innoventric's innovative device employs a heterotopic, cross-caval approach to treat TR by anchoring a prosthetic valve to the vena cava rather than the heart, thus reducing risks of leakage and simplifying the implantation process. The company has already treated over 40 patients and received FDA clearance for an Early Feasibility Study in the U.S. Innoventric's technology aims to address the severe medical issue affecting millions, particularly those who may not qualify for traditional treatments. With a focus on data-driven innovation, Innoventric is positioned to significantly improve patient outcomes in the $10 billion annual transcatheter heart valve replacement market.

Story Coverage
Bias Distribution
100% Center
Information Sources
5a2a5aad-a68d-4ad4-a0bb-fd4b8b61f120
Center 100%
Coverage Details
Total News Sources
1
Left
0
Center
1
Right
0
Unrated
0
Last Updated
12 days ago
Bias Distribution
100% Center
Related News
Daily Index

Negative

21Serious

Neutral

Optimistic

Positive

Ask VT AI
Story Coverage
Subscribe

Stay in the know

Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Related News
Recommended News